112 related articles for article (PubMed ID: 215232)
21. Plasminogen activation: biochemistry, physiology, and therapeutics.
Wun TC
Crit Rev Biotechnol; 1988; 8(2):131-48. PubMed ID: 2976309
[TBL] [Abstract][Full Text] [Related]
22. Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
Stephens RW; Fordham CJ; Doe WF
Eur J Cancer Clin Oncol; 1987 Feb; 23(2):213-22. PubMed ID: 2965017
[TBL] [Abstract][Full Text] [Related]
23. In vitro effects of urokinase--prevention by different inhibitors.
Oethinger MD; Seifried E
Thromb Haemost; 1990 Nov; 64(3):402-6. PubMed ID: 1710833
[TBL] [Abstract][Full Text] [Related]
24. Zymogen-activation kinetics. Modulatory effects of trans-4-(aminomethyl)cyclohexane-1-carboxylic acid and poly-D-lysine on plasminogen activation.
Petersen LC; Brender J; Suenson E
Biochem J; 1985 Jan; 225(1):149-58. PubMed ID: 2579638
[TBL] [Abstract][Full Text] [Related]
25. [Enzymatic fibrinolytic agents].
Jamet M; Granthil C; Levy G
Ann Anesthesiol Fr; 1978; 19(8):693-6. PubMed ID: 31112
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the plasminogen activator urokinase by alpha-tocopherol.
Ogston D
Acta Haematol; 1982; 67(2):114-8. PubMed ID: 6801892
[TBL] [Abstract][Full Text] [Related]
27. Purification of a plasminogen activator inhibitor indistinguishable from alpha1-antitrypsin and an urokinase inhibitor in pregnancy plasma.
Clemmensen I; Thorsen S; Müllertz S
Haemostasis; 1976; 5(4):218-30. PubMed ID: 826461
[TBL] [Abstract][Full Text] [Related]
28. An inhibitor of plasminogen activator in rabbit endothelial cells.
Loskutoff DJ; Edgington TS
J Biol Chem; 1981 May; 256(9):4142-5. PubMed ID: 6783654
[TBL] [Abstract][Full Text] [Related]
29. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor.
Cubellis MV; Andreasen P; Ragno P; Mayer M; Danø K; Blasi F
Proc Natl Acad Sci U S A; 1989 Jul; 86(13):4828-32. PubMed ID: 2544876
[TBL] [Abstract][Full Text] [Related]
30. Studies on interactions between plasminogen activator-containing fluids and avain and murine lymphocytes.
Wainberg MA; Cohen SD
Dev Comp Immunol; 1981; 5(4):649-60. PubMed ID: 6274714
[No Abstract] [Full Text] [Related]
31. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
32. [Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)].
Félez J; Rueda F
Sangre (Barc); 1985; 30(4-C):779-86. PubMed ID: 3937250
[No Abstract] [Full Text] [Related]
33. Cellular and extracellular plasminogen activator and inhibitor in an experimental tumour.
Dong Q; Zhou MH; Subbarao V; Ts'ao CH
Br J Exp Pathol; 1988 Oct; 69(5):685-95. PubMed ID: 3143395
[TBL] [Abstract][Full Text] [Related]
34. Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.
Edelberg JM; Weissler M; Pizzo SV
Biochem J; 1991 Jun; 276 ( Pt 3)(Pt 3):785-91. PubMed ID: 1829607
[TBL] [Abstract][Full Text] [Related]
35. Transformation-dependent activation of urokinase-type plasminogen activator by a plasmin-independent mechanism: involvement of cell surface membranes.
Berkenpas MB; Quigley JP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7768-72. PubMed ID: 1652763
[TBL] [Abstract][Full Text] [Related]
36. Comparative studies on human activators of plasminogen.
Mackie M; Booth NA; Bennett B
Br J Haematol; 1981 Jan; 47(1):77-90. PubMed ID: 6449216
[TBL] [Abstract][Full Text] [Related]
37. Blocking of the fibrinolytic antiactivator by substituted benzoates.
Nanninga L; Guest M
Life Sci; 1974 Jun; 14(12):2507-11. PubMed ID: 4283613
[No Abstract] [Full Text] [Related]
38. Prourokinase activation on the surface of human rhabdomyosarcoma cells: localization and inactivation of newly formed urokinase-type plasminogen activator by recombinant class 2 plasminogen activator inhibitor.
Pöllänen J; Vaheri A; Tapiovaara H; Riley E; Bertram K; Woodrow G; Stephens RW
Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2230-4. PubMed ID: 2138329
[TBL] [Abstract][Full Text] [Related]
39. Occupancy of the cancer cell urokinase receptor (uPAR): effects of acid elution and exogenous uPA on cell surface urokinase (uPA).
Baker MS; Liang XM; Doe WF
Biochim Biophys Acta; 1992 Sep; 1117(2):143-52. PubMed ID: 1381963
[TBL] [Abstract][Full Text] [Related]
40. Limited cleavage of cellular fibronectin by plasminogen activator purified from transformed cells.
Quigley JP; Gold LI; Schwimmer R; Sullivan LM
Proc Natl Acad Sci U S A; 1987 May; 84(9):2776-80. PubMed ID: 3033662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
